Market Overview

IDEXX Labs Is 'Top Dog'

Share:
IDEXX Labs Is 'Top Dog'

IDEXX Laboratories, Inc. (NASDAQ: IDXX) hosted last week its annual Analyst Day presentation which prompted analysts at Bank of America to upgrade the stock and label it a "top dog." The firm's Derik de Bruin upgrades Idexx's stock rating from Neutral to Buy with an unchanged $175 price target.

Idexx's management didn't quantify its near-term outlook but provided sufficient data points to support its long-term targets of:

    1. 10 percent organic revenue growth.
    2. 15 to 20 percent earnings per share compounded annual growth through 2022.

The most "striking" new dataset suggested that out of the total approximately 200 million annual clinical veterinarian visits in the U.S., a mere 80 million included any sort of Dx test, and a smaller 24 million visits included a chemistry panel.

As such, the analyst left the presentation "feeling more positive" on the various levers the company has to drive growth, including higher Dx (diagnostic) utilization from its installed base, a ramp-up of new products, and continued innovation.

Meanwhile, the animal Dx market is "still largely untapped" and Idexx doesn't have to deal with a heightened competitive environment over the near-term, de Bruin continued.

Idexx's stock is trading at 42x the analyst's 2018 earnings per share estimate, which does mark a premium to the broader peer group, but this is justified given management's achievable outlook of 10 percent long-term revenue growth and 15–20 percent earnings per share growth, the analyst concluded. Encouragingly, there is room for additional upside to the long-term guide from new product launches and the analyst believes that a "slightly more aggressive outlook is warranted."

Related Links:

A Peek Into The Markets: U.S. Stock Futures Rise; All Eyes On Jackson Hole Meeting

12 Stocks To Watch For August 24, 2017

Latest Ratings for IDXX

DateFirmActionFromTo
Aug 2020Credit SuisseMaintainsOutperform
Jul 2020StifelMaintainsBuy
Jul 2020B of A SecuritiesMaintainsBuy

View More Analyst Ratings for IDXX
View the Latest Analyst Ratings

 

Related Articles (IDXX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Reiteration Events Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
JBLRBC CapitalMaintains38.0
COSTRBC CapitalMaintains412.0
COSTMKM PartnersMaintains325.0
NOWStifelMaintains500.0
MTNTruist SecuritiesMaintains243.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com